[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632420":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":11,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":11,"enrollmentInfo":37,"targetDuration":11,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":11,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":11},{"fullName":5,"class":6},"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HW211026 dose 1","EXPERIMENTAL",null,[13],"Drug: HW211026",{"label":15,"type":10,"description":11,"interventionNames":16},"HW211026 dose 2",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","HW211026","HW211026 ointment dose 1，applied topically on face once daily.",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"HW211026 ointment dose 2，applied topically on face once daily.",[15],{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632420","phase-2-a-phase-2-study-of-hw211026-in-participants-with-actinic-keratosis-100632420",false,"NCT07513454","A Phase 2 Study of HW211026 in Participants With Actinic Keratosis","A Multicenter, Randomized, Open-label, Parallel-group, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HW211026 Ointment in Patients With Actinic Keratosis.","Key Inclusion Criteria:\n\n* Aged ≥ 18 years, male or female.\n* At least 2 clinically typical target actinic keratosis lesions on the face.\n* Willing to avoid direct sun or ultraviolet exposure to the treatment area during the trial.\n* Fully informed about the study, voluntarily sign the informed consent form, and be able to comply with study procedures and follow-up examination requirements.\n\nKey Exclusion Criteria:\n\n* Clinically atypical and\u002For rapidly changing actinic keratosis lesions, such as hypertrophic lesions, hyperkeratotic lesions, and\u002For cutaneous horns.\n* Presence of incompletely healed wounds or suspected squamous cell carcinoma, basal cell carcinoma, or other malignant tumors within 5 cm of the actinic keratosis lesions.\n* Participants with other skin diseases or skin conditions that, in the investigator's judgment, may interfere with the evaluation of safety or efficacy.\n* Participants who are unable to discontinue immunomodulators, immunosuppressants, cytotoxic agents, or corticosteroids from 1 month prior to signing the informed consent form until study completion or early withdrawal.\n* Participants who have undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial, as determined by the investigator.\n* Participants who have participated in any investigational drug clinical trial and received an investigational product within 3 months prior to screening.","ALL","18 Years",{"count":38,"type":39},80,"ESTIMATED","INTERVENTIONAL",[42],"PHASE2","This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.",[45],"Actinic Keratosis","NOT_YET_RECRUITING","2026-03-31",{"date":49,"type":50},"2026-04-07","ACTUAL",{"date":52,"type":39},"2026-05",{"date":54,"type":39},"2027-12",{"name":5,"class":6}]